Point of Care Hematology Diagnostics Market Expected to Reach $3.6 Billion by 2030

According to a new report published by Allied Market Research, titled, “Point of Care Hematology Diagnostics Market," The point of care hematology diagnostics market size  was valued at $2.4 billion in 2023, and is estimated to reach $3.6 billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030.

Point-of-care (POC) hematology diagnostics refers to medical tests conducted near or at the site of patient care to assess blood-related parameters, providing immediate results that facilitate rapid clinical decisions. POC hematology diagnostics enable quicker clinical decisions and interventions by providing immediate insights into a patient's hematological condition. This reduces reliance on centralized laboratory tests, leading to faster diagnosis, improved patient care, and better overall outcomes. The ability to deliver real-time results helps healthcare providers address critical health issues promptly and efficiently.

The global point of care hematology diagnostics market growth is driven by the rise in prevalence of blood disorders, including anemia, thalassemia, and other hematological conditions. These diseases require rapid and reliable diagnostic solutions to ensure timely and effective medical interventions, particularly in critical care and primary healthcare settings. As a result, the adoption of point-of-care hematology devices has increased due to their ability to deliver quick and accurate results with minimal blood samples.

In addition, supportive government policies and initiatives focused on strengthening healthcare delivery systems and improving accessibility to diagnostic tools further propel point of care hematology diagnostics market growth. These initiatives often include funding for point-of-care testing and training programs aimed at rural and underserved regions. For instance, in November 2024, scientists from Johns Hopkins secured a $1.7 million grant from the Bill & Melinda Gates Foundation to develop a point-of-care diagnostic tool for anemia.

This two-year project aims to make anemia screening more accessible worldwide, especially in low-resource areas. The team is developing a low-cost, accurate, and non-invasive test for diagnosing anemia, intending to introduce a new platform for managing the condition in under-resourced settings. The technology, called Back-illumination Capillary Analysis (BCA), measures total blood hemoglobin by analyzing images of a patient’s finger using a hyperspectral camera and AI. This method eliminates the need for blood tests, making it a quick and simple solution suitable for diverse and low-resource population.

Furthermore, the integration of digital technologies, particularly AI and cloud-based data management, is transforming the diagnostic landscape, which is expected to drive point of care hematology diagnostics market opportunity. These advancements improve the accuracy & speed of hematological testing and enable better data tracking & remote monitoring. For instance, the Hilab Lens is a compact point-of-care (POC) device designed to perform complete blood counts (CBC) using a minimal blood sample obtained via fingerstick.

Utilizing digital microscopy, it delivers results within approximately 30 minutes, facilitating rapid diagnostics in various healthcare settings. The device uses artificial intelligence (AI) and Internet of Things (IoT) technologies to enhance diagnostic accuracy and efficiency. Its innovative design was recognized with the "Gold" award from the iF DESIGN Awards in 2022. Collectively, these factors are shaping a more efficient and accessible point-of-care hematology diagnostics ecosystem globally.

However, the lack of skilled professionals capable of operating advanced diagnostic devices in decentralized or resource-limited settings restricts market growth. While POC devices are designed for ease of use, accurate interpretation of results and proper handling of equipment still require a certain level of technical training. In rural or underserved areas, the shortage of trained healthcare personnel limits the optimal use of these technologies, potentially leading to errors in diagnosis or underutilization of equipment. This skill gap hampers the widespread adoption of point of care hematology diagnostics market trends, particularly in developing regions where the need for rapid diagnostics is more.

The point of care hematology diagnostics industry is segmented into test type, mode of prescription, end user, and region. By test type, the market is segregated into complete blood count (CBC), coagulation testing, hemoglobin testing & anemia diagnosis, and others. The complete blood count (CBC) segment dominated the point of care hematology diagnostics market share in 2023, this was attributed to the widespread use as a first-line diagnostic tool for detecting a variety of hematological conditions, including anemia and leukemia. Its ability to provide rapid, comprehensive insights into overall blood health makes it indispensable in routine check-ups and emergency care. In addition, advancements in portable CBC analyzers have further driven adoption in point-of-care testing and drives the segment growth.

However, the coagulation testing segment is expected to register the highest CAGR during the point of care hematology diagnostics market forecast period. This growth is attributed to the rising prevalence of bleeding disorders, increased demand for anticoagulant therapy monitoring, and the adoption of rapid, point-of-care solutions that provide timely and accurate coagulation status results.

Depending on the mode of prescription, the point of care hematology diagnostics market analysis is segmented into prescription-based products and OTC based products. The prescription-based products segment dominated the point of care hematology diagnostics market share in 2023. This was attributed to the higher reliability, clinical accuracy, and regulatory approval associated with these devices, which are commonly used in hospitals, diagnostic centers, and physician offices. Their integration into routine patient management, especially for chronic and critical conditions, supports consistent monitoring under professional supervision. Moreover, healthcare providers prefer prescription-based devices due to their compliance with established diagnostic protocols and patient safety standards.

However, the OTC based products segment is expected to register the highest CAGR during the forecast period. This growth is attributed to increase in demand for self-monitoring tools, growing consumer awareness about early diagnosis, and the rising trend of home-based healthcare. The convenience, affordability, and ease of use of OTC hematology products empower individuals to manage health conditions such as anemia or monitor hemoglobin levels without visiting a clinic. In addition, advancements in point of care testing and mobile-integrated diagnostics are enhancing the accessibility and appeal of these devices across a broader population testing & anemia diagnosis, and others.

The complete blood count (CBC) segment dominated the market share in 2023, this was attributed to the widespread use as a first-line diagnostic tool for detecting a variety of hematological conditions, including anemia and leukemia. Its ability to provide rapid, comprehensive insights into overall blood health makes it indispensable in routine check-ups and emergency care. In addition, advancements in portable CBC analyzers have further driven adoption in point-of-care testing and drives the segment growth.

However, the coagulation testing segment is expected to register the highest CAGR during the forecast period. This growth is attributed to the rising prevalence of bleeding disorders, increased demand for anticoagulant therapy monitoring, and the adoption of rapid, point-of-care solutions that provide timely and accurate coagulation status results.

Depending on the mode of prescription, the point of care hematology diagnostics industry is segmented into prescription-based products and OTC based products. The prescription-based products segment dominated the point of care hematology diagnostics market size in 2023. This was attributed to the higher reliability, clinical accuracy, and regulatory approval associated with these devices, which are commonly used in hospitals, diagnostic centers, and physician offices. Their integration into routine patient management, especially for chronic and critical conditions, supports consistent monitoring under professional supervision. Moreover, healthcare providers prefer prescription-based devices due to their compliance with established diagnostic protocols and patient safety standards.

However, the OTC based products segment is expected to register the highest CAGR during the forecast period. This growth is attributed to increase in demand for self-monitoring tools, growing consumer awareness about early diagnosis, and the rising trend of home-based healthcare. The convenience, affordability, and ease of use of OTC hematology products empower individuals to manage health conditions such as anemia or monitor hemoglobin levels without visiting a clinic. In addition, advancements in point of care testing and mobile-integrated diagnostics are enhancing the accessibility and appeal of these devices across a broader population.